The global vascular sealant market is projected to reach USD 1,850.0 million in 2026 and expand to USD 3,150.0 million by 2036, registering a CAGR of 5.5% over the forecast period. According to the opinion of FMI, market growth is associated with the growing number of vascular, endovascular, and cardiac procedures, as well as the growing importance of intraoperative bleeding control and the reduction of post-procedural complications. The use of fibrin-based, collagen-based, PEG-based synthetic and cyanoacrylate-based sealants is being driven by their ability to complement sutures and staples and enhance procedural efficiency. Improvements in sealant composition, delivery systems, and applicators are making it possible for surgeons to reliably seal.
"Acquiring Vivasure expands Haemonetics' complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large-bore closure market and our impact in fast-growing structural heart and endovascular procedures." said Ken Crowley, Vice President & General Manager, Interventional Technologies at Haemonetics.
Large firms are also consolidating their market share through innovation in sealant technology, formulation, and clinical application. Baxter International is a leading firm in the fibrin-based surgical sealant market for vascular and cardiovascular surgery. Johnson & Johnson (Ethicon) has been exploring adjunctive hemostatic and sealant therapies that complement its overall surgical business. Medtronic is also developing vascular sealing applications for open and minimally invasive procedures. However, B. Braun, CSL Behring, and Grifols are also developing biologic sealants, which show a trend in the industry toward an overall surgical hemostasis and sealing solution.
Market development is further aided by the growing use of vascular sealants in hospitals, ambulatory surgery centers, and specialty cardiac and vascular centers. Open vascular surgery and endovascular or hybrid procedures are both fueling demand, with sealants being employed for anastomotic sealing, graft reinforcement, needle-hole bleeding, soft tissue adjunct sealing, and access site management. Demand from end-users is still largely channeled through hospitals, aided by growing procedural volumes and an increasing adoption of advanced surgical adjuncts. In sum, the market dynamics are shifting towards more diversified product lines of sealants that integrate biological and synthetic chemistries with optimal delivery systems.
Future Market Insights projects the vascular sealant market to expand at a CAGR of 5.5% from 2026 to 2036, increasing from USD 1,850.0 million in 2026 to USD 3,150.0 million by 2036.
FMI Research Approach: Bottom-up revenue estimation mapped across sealant chemistry, form factor, use case, clinical setting, and end-user categories, with procedure-volume anchoring through 2036.
Future Market Insights analysts note that demand is increasingly being shaped by a shift from conventional hemostatic solutions toward performance-oriented sealing adjuncts embedded into standardized vascular workflows.
FMI Research Approach: Assessed product differentiation through application ease, biocompatibility, degradation predictability, and compatibility across open, endovascular, and hybrid procedures.
Future Market Insights notes that high vascular intervention volumes, mature cardiovascular infrastructure, are supporting the United States and stronger adoption of adjunct technologies aligned with protocol-driven surgery.
FMI Research Approach: Gathered country-level inputs on procedure density, hospital capability, purchasing behavior, and utilization intensity across high-volume vascular centers.
The global vascular sealant market is projected to reach USD 3,150.0 million by 2036.
FMI Research Approach: Forecasts were derived using segment-weighted utilization assumptions across key surgical use environments and application frequency across procedure mix.
According to Future Market Insights analysts, rising scrutiny on safety, biocompatibility, and repeatable clinical performance is accelerating preference for sealing solutions that reduce bleeding and leakage variability.
FMI Research Approach: Incorporated quality expectations, risk-reduction priorities, and standard-of-care alignment into models to refine adoption curves across sealant chemistries and ready-to-use formats.
| Metric | Value |
|---|---|
| Market Value (2026) | USD 1,850.0 million |
| Market Forecast Value (2036) | USD 3,150.0 million |
| Forecast CAGR (2026-2036) | 5.5% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research.
The increasing focus on surgical standardization and outcomes-driven accountable care is driving the adoption of vascular sealants. The reduced acceptance of variability in bleeding control, anastomotic security, and complication rates is accelerating the adoption of complementary sealing approaches that ensure predictable outcomes. This has led to the adoption of sealants as workflow-enabling technologies that facilitate intraoperative efficiency and outcomes, rather than being viewed as complements or add-ons. Commercially available fibrin-based and synthetic sealants are being increasingly positioned for controlled sealing in open and hybrid vascular surgery, which is in line with institutional approaches to optimize operative efficiency and accelerate recovery.
The vascular sealant market has been segmented based on sealant chemistry, form factor, use case, setting, end user, and geography. By sealant chemistry, the market is divided into fibrin-based sealants, PEG-based synthetic sealants, cyanoacrylates, collagen or gelatin-based sealants, and polysaccharide or other formulations. By form factor, the market includes liquid, patch, spray or foam, and pre-filled applicator kits. Based on use case, the market is categorized into anastomotic sealing, graft sealing, needle-hole bleeding control, adjunct soft-tissue sealing, and access-site adjunct. By setting, the market spans open vascular surgery, endovascular or hybrid procedures, and cardiac surgery. By end user, the market is segmented into hospitals, ambulatory surgery centers (ASCs), and specialty cardiac or vascular centers. Regionally, the market covers the USA, Germany, the UK, France, Japan, China, and Saudi Arabia.
Fibrin-based sealants currently dominate the chemistry category with a 34.0% market share, thanks to their biomimetic approach and high level of clinical acceptance in vascular procedures. These products work by recreating the end-process of coagulation, allowing for the quick achievement of clotting and hemostasis in high-pressure arterial and venous environments. From a clinical perspective, they are often chosen for their predictable performance and versatility, especially in anastomotic reinforcement and graft closure in open vascular surgery. Their widespread use has also helped to establish them as the standard against which new synthetic and hybrid products are measured.
Anastomotic sealing is the largest use-case segment, accounting for 36.0% of the total demand, due to the large demand for leak and bleeding prevention at vascular junctions. Precision sealing at anastomotic sites is a highly required application for reducing postoperative complication rates and re-intervention rates, thus making sealants a crucial adjunct rather than a discretionary product in vascular surgery.
The market for vascular sealants is gradually moving away from the traditional dependence on sutures and mechanical closure alone to more sophisticated sealant systems that offer immediate and localized hemostasis. The traditional approach is gradually being perceived as inadequate in complex vascular procedures, where the friability of tissue and high intraluminal pressures increase the risk of bleeding. Sealants are thus being incorporated directly into the traditional vascular closure strategies rather than being selectively used. This has also increased the expectations of sealant performance in terms of consistency, deliverability, and functionality in different anatomical settings. Sealants that can be easily incorporated into surgical practice without prolonging surgery times are being given preference, thus reemphasizing the importance of sealants as critical surgical tools.
The growing focus on postoperative care, complication prevention, and reducing length of stay is also changing the way sealants are chosen. Vascular procedures are now being evaluated based on parameters such as bleeding-related re-interventions and graft integrity, which is forcing the surgical community to adopt tools that can improve the reliability of these procedures. Sealants that have proven clinical performance and a reliable degradation profile are now being preferred because of these accountability-based models of care. The choice of sealants is no longer based solely on their hemostatic performance but also on their effects on recovery and resource utilization, thereby solidifying the position of sealants in value-based surgical care.
In the period from 2026 to 2036, the long-term leadership position in the vascular sealant market is expected to remain in favor of those suppliers who can support high-volume hospital-based procedures and also meet the demands of hybrid and endovascular procedures.
The vascular sealant market is experiencing a shift towards becoming a standardized part of the surgical infrastructure, rather than a discretionary part. Those suppliers who can integrate clinical efficacy, workflow, and applicability are expected to unlock long-term value as the volume of vascular interventions continues to grow.
The global market for vascular sealant products is increasing because of the growing optimization of surgical and interventional procedures for faster hemostasis, less blood loss, and efficient procedural delivery. The market for products is being driven by the growing number of cardiovascular, endovascular, and minimally invasive procedures, and the growing interest in optimizing complications and hospital stays associated with procedures. The market for products is being driven by the growing interest in sealing, biocompatibility, ease of use, and compatibility with different surgical work flows and not the number of procedures. China is expected to have a CAGR of 6.7%, Saudi Arabia 6.2%, the USA 5.9%, Germany 4.8%, the UK 4.6%, France 4.4%, and Japan 3.9% over the 2026-2036 period. The development of the market is firmly grounded in clinical outcomes, work flow integration, and predictive outcomes and not rapid unit growth.
| Country | CAGR (2026-2036) |
|---|---|
| USA | 5.9% |
| Germany | 4.8% |
| UK | 4.6% |
| France | 4.4% |
| Japan | 3.9% |
| China | 6.7% |
| Saudi Arabia | 6.2% |
Source: FMI historical analysis and forecast data.
In the Chinese market, the demand for vascular sealants is being fueled by the fast development of surgical infrastructure and the adoption of minimally invasive and catheter-based procedures in large tertiary hospitals. As a result of the increasing number of procedures and the need for efficiency, vascular sealants are being increasingly adopted in order to achieve faster vessel closure and minimize post-procedure complications. The increasing focus on the development of Chinese clinical capabilities is also fueling the adoption of vascular sealants in public healthcare settings. As a result of this focus, the Chinese market for vascular sealants is expected to register a 6.7% CAGR during the forecast period.
Looking ahead into the next five years, there will be an increased adoption of vascular sealants in secondary hospitals due to the increasing standardization of interventional procedures and familiarity with the technology. There will be a growing preference for vascular sealants that can achieve rapid polymerization, predictable performance, and are appropriate for high-volume procedural settings.
In the case of Saudi Arabia, the market is being driven by the modernization of the healthcare system and increased investment in highly advanced surgical and intervention capabilities. Vascular sealants are also being increasingly used to support complex cardiovascular procedures, reduce intraoperative bleeding, and improve post-operative recovery outcomes. The expansion of specialty hospitals and centers of excellence is also driving demand for highly advanced hemostatic solutions. In line with this trend, the Saudi Arabia vascular sealant market is expected to register a 6.2% CAGR during the study period.
Going forward, there is expected to be increased usage in high acuity care environments, driven by the adoption of international surgical standards and ongoing investment in clinician education and advanced medical technology.
In Germany, the vascular sealant market is being sustained by a precision-oriented surgical culture where standardised technique, tight documentation, and outcomes benchmarking keep adoption steady rather than cyclical. Hospitals and surgical centres increasingly treat haemostasis as a controllable quality variable, using sealants to reduce intraoperative bleeding, support complex cardiac and vascular reconstructions, and minimise downstream complications that extend length of stay. Demand is reinforced by structured procurement and reimbursement environments that favour clinically validated products with repeatable performance across routine and high-complexity procedures. In line with this stability dynamic, the Germany vascular sealant market is expected to register a 4.8% CAGR during the study period.
Going forward, market continuity is expected to be maintained through protocol-led expansion in high-acuity operating rooms and interventional suites, supported by surgeon education, simulation-based skills training, and wider adoption of international surgical standards. As German providers intensify focus on complication avoidance and faster recovery, vascular sealants will remain reliability tools embedded in defined care pathways.
In the United Kingdom, the adoption of vascular sealants is being driven by the growing need for value-based healthcare, procedural optimization, and the minimization of post-operative complications in the public and private healthcare settings. The use of vascular sealants is being considered for their potential to reduce procedure time and enable rapid patient recovery in cardiovascular and minimally invasive procedures. In this setting, the UK vascular sealant market is expected to register a 4.6% CAGR during the forecast period.
Future adoption is expected to be driven by strategic adoption in complex and high-risk procedures, with broader adoption tempered by procurement and budgetary factors.
The development of the market in France is also being influenced by the controlled launch of vascular sealants. Hospitals are embracing technologies that have already been validated to offer clinical benefits, are cost-effective, and are compatible with current practices before mass adoption. With the continued validation of the clinical effectiveness of vascular sealants in the prevention of complications from bleeding, their adoption is gradually gaining traction. Thus, the vascular sealant market in France is expected to register a CAGR of 4.4% during the forecast period.
In the next few years, incremental growth is expected as pilot projects and acceptance gain momentum in cardiovascular and general surgery.
In the Japanese market, the demand is being driven by a highly regulated healthcare setting where the aspects of clinical reliability, safety, and standardization are of utmost importance. The demand for vascular sealants is being driven in the most specialized surgical centers, with a cautious adoption that is in line with the conservative adoption of technology. Although the adoption is being done at a relatively slower pace compared to other geographies, the integration with the existing workflows is helping to sustain the demand. In this setting, the Japanese market for vascular sealants is expected to register a CAGR of 3.9% during the forecast period.
The future demand is expected to be driven by improvements in the formulation and usability of these products, which will help them align with the efficiency-oriented surgical practices in Japan.
In the United States, market development is being fueled by the need to improve surgical efficiency, reduce the rate of complications, and manage procedural costs in high-volume healthcare environments. Vascular sealants are being increasingly employed to enable rapid hemostasis, decrease procedural times, and improve post-procedure outcomes in cardiovascular and interventional procedures. Healthcare environments in the United States are favoring products that have demonstrated stable performance and compatibility with existing surgical practices. In this mature market and environment, the USA vascular sealant market is expected to grow at a 5.9% CAGR during the forecast period.
Market development over the next five years is expected to be fueled by the adoption of expanded indications, incremental innovation, and growing usage in minimally invasive and catheter-based procedures.
The competitive environment in the vascular sealant market is fueled by the rising importance of ease of use, hemostasis efficacy, and compatibility with open and minimally invasive vascular procedures. The rising number of cardiovascular and peripheral vascular procedures, as well as the need to lower procedural time and complications is fueling the market dynamics. The different types of Sealant Chemistry such as fibrin, PEG-based synthetic, cyanoacrylate, and collagen/gelatin-based vascular sealants are fueling the market demand.
The leading companies are enhancing their market presence with diversified product offerings across various Form Factors, such as liquid, patch, spray/foam, and pre-filled applicator kits. Baxter International has a strong market presence with fibrin-based sealants that are mainly used in open vascular surgery environments. Johnson & Johnson (Ethicon) continues to enhance its market presence across both liquid and patch-type sealants, which target anastomotic sealing and graft sealing. Medtronic has utilized its cardiovascular device portfolio to support the adoption of sealants in open and endovascular or hybrid procedures.
Concurrently, companies such as B. Braun, CSL Behring, and Grifols are also strengthening their position in the market with biologic and plasma-derived sealants. In the USA, Germany, the UK, France, China, Japan, and Saudi Arabia, competitive differentiation is being fueled by adaptability in use cases, clinical versatility, and a strong penetration of end-users in the hospital setting.
Key Industry Developments:
The market for vascular sealants is divided into segments as the global market demand for surgical sealant products used for hemostasis and tissue sealing in vascular surgery. The market value is expressed in USD million and forecasted from 2026 to 2036.The vascular sealants market comprises the demand for sealant products used in vascular surgery for anastomotic sealing, graft sealing, bleeding control, and access site adjunct use. The products are used in open vascular surgery, endovascular or hybrid procedures, and cardiac surgery.
The vascular sealants market is segmented by sealant chemistry, including fibrin, PEG-based synthetic, cyanoacrylate, collagen/gelatin-based, and polysaccharide/other sealants. The form factors, including liquid, patch, spray/foam, and pre-filled applicator kits. The use cases included in the analysis are anastomotic sealing, graft sealing, needle-hole bleeding, adjunct soft-tissue sealing, and access site adjunct. The end users included in the analysis are Hospitals, ASCs, and Specialty cardiac/vascular centers.
Conventional sutures, staples, clips, and mechanical closure devices that are not intended for hemostasis through the use of a sealant. Topical wound care adhesives, non-vascular surgical sealants, diagnostic hemostasis devices, and therapeutic biologics that are not intended for use in vascular sealing are excluded from the vascular sealant market.
| Items | Values |
|---|---|
| Quantitative Units | USD 1,850.0 Million |
| Sealant Chemistry | Fibrin, PEG-based synthetic, Cyanoacrylate, Collagen / gelatin-based, Polysaccharide / other |
| Form Factor | Liquid, Patch, Spray / foam, Pre-filled applicator kits |
| Use Case | Anastomotic sealing, Graft sealing, Needle-hole bleeding control, Adjunct soft-tissue sealing, Access-site adjunct |
| Setting | Open vascular surgery, Endovascular / hybrid, Cardiac surgery |
| End User | Hospitals, ASCs, Specialty cardiac/vascular centers |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Countries Covered | USA, Germany, UK, France, China, Japan, Saudi Arabia, and 40+ countries |
| Key Companies Profiled | Baxter International; Johnson & Johnson (Ethicon); Medtronic; B. Braun; CSL Behring, Grifols, Integra LifeSciences, Artivion (CryoLife), Smith+Nephew and Teleflex |
| Additional Attributes | Dollar sales by sealant chemistry and use case; adoption trends across settings; impact of form-factor innovation and hospital procurement dynamics |
Source: FMI historical analysis and forecast data.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Vascular Sealant Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
